SINGAPORE (May 1): Swiss pharmaceutical company Lonza Group, which has a secondary listing on SGX, has announced a ten-year deal with US-based Moderna to undertake large scale manufacturing of the latter’s mRNA-1273, which is a vaccine that is being tested for use against the novel coronavirus. 

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply